| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ADXN Stock Overview
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.92 |
| 52 Week High | CHF1.98 |
| 52 Week Low | CHF0.80 |
| Beta | 1.33 |
| 1 Month Change | -12.80% |
| 3 Month Change | -23.97% |
| 1 Year Change | -46.04% |
| 3 Year Change | -59.65% |
| 5 Year Change | -60.00% |
| Change since IPO | -98.65% |
Recent News & Updates
Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Shareholder Returns
| ADXN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -1.1% | -1.2% | -4.4% |
| 1Y | -46.0% | -37.0% | 8.8% |
Return vs Industry: ADXN underperformed the Swiss Biotechs industry which returned -37.7% over the past year.
Return vs Market: ADXN underperformed the Swiss Market which returned 8.9% over the past year.
Price Volatility
| ADXN volatility | |
|---|---|
| ADXN Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: ADXN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ADXN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 27 | Tim Dyer | https://www.addextherapeutics.com |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction.
Addex Therapeutics Fundamentals Summary
| ADXN fundamental statistics | |
|---|---|
| Market Cap | CHF34.87m |
| Earnings (TTM) | -CHF13.05m |
| Revenue (TTM) | CHF4.64m |
7.5x
P/S Ratio-2.7x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXN income statement (TTM) | |
|---|---|
| Revenue | CHF4.64m |
| Cost of Revenue | CHF11.84m |
| Gross Profit | -CHF7.20m |
| Expenses | CHF5.86m |
| Earnings | -CHF13.05m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Mar 07, 2022
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -154.98% |
| Net Profit Margin | -281.08% |
| Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparisonValuation
Is Addex Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ADXN (CHF0.92) is trading below our estimate of fair value (CHF4.47)
Significantly Below Fair Value: ADXN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ADXN is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ADXN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADXN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADXN's PB Ratio (2.6x) is in line with the CH Biotechs industry average.
Future Growth
How is Addex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
42.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADXN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).
Earnings vs Market: ADXN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ADXN's is expected to become profitable in the next 3 years.
Revenue vs Market: ADXN's revenue (35.8% per year) is forecast to grow faster than the Swiss market (4.8% per year).
High Growth Revenue: ADXN's revenue (35.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADXN's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Addex Therapeutics performed over the past 5 years?
-38.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADXN is currently unprofitable.
Growing Profit Margin: ADXN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADXN is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.
Accelerating Growth: Unable to compare ADXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADXN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: ADXN has a negative Return on Equity (-97.84%), as it is currently unprofitable.
Financial Health
How is Addex Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ADXN's short term assets (CHF17.4M) exceed its short term liabilities (CHF3.3M).
Long Term Liabilities: ADXN's short term assets (CHF17.4M) exceed its long term liabilities (CHF1.4M).
Debt to Equity History and Analysis
Debt Level: ADXN is debt free.
Reducing Debt: ADXN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADXN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADXN is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
Dividend
What is Addex Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADXN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.2yrs
Average management tenure
CEO
Tim Dyer (53 yo)
20yrs
Tenure
Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD997.89K) is above average for companies of similar size in the Swiss market ($USD561.45K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: ADXN's management team is seasoned and experienced (5.2 years average tenure).
Board Members
Experienced Board: ADXN's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.6%.
Top Shareholders
Company Information
Addex Therapeutics Ltd's employee growth, exchange listings and data sources
Key Information
- Name: Addex Therapeutics Ltd
- Ticker: ADXN
- Exchange: SWX
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF34.868m
- Shares outstanding: 37.90m
- Website: https://www.addextherapeutics.com
Number of Employees
Location
- Addex Therapeutics Ltd
- Chemin des Mines, 9
- Geneva
- Geneva
- 1202
- Switzerland
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/25 21:37 |
| End of Day Share Price | 2022/01/25 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.